These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38241371)

  • 21. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
    Baker M; Cordes L; Brownell I
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma.
    Lin Z; McDermott A; Shao L; Kannan A; Morgan M; Stack BC; Moreno M; Davis DA; Cornelius LA; Gao L
    Cancer Lett; 2014 Mar; 344(2):272-281. PubMed ID: 24262658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Merkel Cell Carcinoma Therapeutic Update.
    Cassler NM; Merrill D; Bichakjian CK; Brownell I
    Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and preclinical treatment options for Merkel cell carcinoma.
    Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
    Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be Reverted by Therapeutic Intervention.
    Schlemeyer T; Ohnezeit D; Virdi S; Körner C; Weißelberg S; Starzonek S; Schumacher U; Grundhoff A; Indenbirken D; Albertini S; Fischer N
    J Invest Dermatol; 2022 Nov; 142(11):3071-3081.e13. PubMed ID: 35636504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma.
    Temblador A; Topalis D; Andrei G; Snoeck R
    Tumour Virus Res; 2022 Dec; 14():200244. PubMed ID: 36007768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Merkel Cell Polyomavirus Status With p53, RB1, and PD-L1 Expression and Patient Prognosis in Merkel Cell Carcinomas: Clinical, Morphologic, and Immunohistochemical Evaluation of 17 Cases.
    Öğüt B; Bayram EK; İnan MA; Kestel S; Erdem Ö
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):371-378. PubMed ID: 37126387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
    Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
    J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
    Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
    BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.
    Winkler JK; Bender C; Kratochwil C; Enk A; Hassel JC
    Br J Dermatol; 2017 Jan; 176(1):216-219. PubMed ID: 27038231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
    Gehrcken L; Sauerer T; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression.
    Srinivas N; Song L; Lei KC; Gravemeyer J; Furtmann F; Gambichler T; Becker JC; Sriram A
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8267-8277. PubMed ID: 37071208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
    Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
    Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
    Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
    J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
    Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.
    Dowlatshahi M; Huang V; Gehad AE; Jiang Y; Calarese A; Teague JE; Dorosario AA; Cheng J; Nghiem P; Schanbacher CF; Thakuria M; Schmults CD; Wang LC; Clark RA
    J Invest Dermatol; 2013 Jul; 133(7):1879-89. PubMed ID: 23419694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of PI3K signaling in Merkel cell carcinoma.
    Nardi V; Song Y; Santamaria-Barria JA; Cosper AK; Lam Q; Faber AC; Boland GM; Yeap BY; Bergethon K; Scialabba VL; Tsao H; Settleman J; Ryan DP; Borger DR; Bhan AK; Hoang MP; Iafrate AJ; Cusack JC; Engelman JA; Dias-Santagata D
    Clin Cancer Res; 2012 Mar; 18(5):1227-36. PubMed ID: 22261808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 in circulating exosomes of Merkel cell carcinoma.
    Zanella A; Vautrot V; Aubin F; Avoscan L; Samimi M; Garrido C; Gobbo J; Nardin C
    Exp Dermatol; 2022 Jun; 31(6):869-877. PubMed ID: 34994009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.